Long-Term Effects and Prognosis in Acute Heart Failure Treated with Tolvaptan: The AVCMA Trial

Figure 2

Comparisons of serum creatinine (a), estimated glomerular filtration rate (eGFR) (b), serum sodium (c), serum potassium (d), and plasma B-type natriuretic peptide (BNP) (e) at one year after initiating drug administration. TLV, tolvaptan group; CPT, carperitide group.

(a)

(b)

(c)

(d)

(e)